Register Login

Keros Therapeutics Inc (KROS)

  • Event
  • May 17, 2022, 20:05 UTC

(10% Negative) Keros Therapeutics, Inc. (KROS) Announces Delay in included Trials for Fulton index Due to Pandemic-Related Challenges, Manufacturing Considerations

Full text
Register to leave comments
  • News bot Oct. 1, 2025, 8:39 p.m.

    📋 Keros Therapeutics, Inc. (KROS) - Clinical Trial Update

    Filing Date: 2022-05-17

    Accepted: 2022-05-17 16:05:11

    Event Type: Clinical Trial Update

    Event Details:

    Keros Therapeutics Inc (KROS) Announces Clinical Trial Update Keros Therapeutics Inc (KROS) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: included, tested
    • Diseases/Conditions: Fulton index, three weeks
    • Clinical Stage: clinical Study, clinical study
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Pandemic-Related Challenges
    • Collaboration: DocumentExhibit 99.1Keros Therapeutics Presents Results

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval: Not available
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Keros Therapeutics Inc
    • CIK: 0001664710
    • Ticker Symbol: KROS
    • Period End Date: 2022-05-17
    • Document Type: 8-K

Search

News categories